Descrizione del progetto
Dare nuova vita alla diagnostica dei carcinomi gastrici
La diagnosi precoce del carcinoma gastrico è associata a un’elevata probabilità di cura. Ciononostante, la mancanza di strumenti di screening non invasivi e affidabili sta ostacolando i progressi, soprattutto in Europa orientale e in America latina. Il progetto VOGAS, finanziato dall’UE, sta sviluppando uno strumento di screening non invasivo per il carcinoma gastrico volto a rilevare modelli caratteristici dei composti organici volatili (COV). Verrà effettuata l’analisi dell’origine e della composizione dei COV nei pazienti affetti da carcinoma gastrico e i COV individuati verranno raffrontati ai composti nel respiro umano mediante l’impiego della gascromatografia associata alla spettrometria di massa, nonché a un modello di reazione su microarray con nanoparticelle d’oro. Negli studi clinici svolti in paesi sottoposti a un elevato carico di malattia verrà sviluppata e convalidata una nuova tipologia di analizzatore del respiro.
Obiettivo
Gastric cancer has good chances to be cured if diagnosed at an early stage; currently, there is lack of a reliable non-invasive screening tool. Eastern Europe and Latin America are among the geographical areas with high burden of the disease.
This project is aiming at developing a non-invasive gastric cancer screening tool by detecting characteristic panels of volatile organic compounds (VOCs). The mechanisms of VOC origin and their composition in gastric cancer patients will be addressed via headspace analysis of cancer tissue, cell-lines, and bacterial flora; VOCs identified during this analysis will be compared to the compounds present in human breath, both via gas chromatography coupled to mass spectrometry (GC-MS).
Based on this data, a new type of breath analyser will be developed and validated building upon previously acquired expertise of the consortium members. Specifically, the exhaled breath analyser will combine electronic nose concepts utilizing gold nanoparticles and metal oxide sensors with orthogonal mid-infrared spectroscopic techniques for obtaining multi-dimensional analytical data sets; furthermore, compact pre-concentration schemes will be evaluated. All components will be integrated into several prototypes of portable and optimized devices.
The clinical studies will be conducted in parallel in European (Latvia, Ukraine) and Latin American (Colombia, Brazil, Chile) countries with high disease burden. Patients with gastric cancer and individuals with and without precancerous lesions (dysplasia, atrophy, intestinal metaplasia) will be enrolled. The role of confounding factors including H.pylori infection will be addressed.
As the main result, we expect to provide the first reliable non-invasive gastric cancer screening device based on exhaled breath analysis concepts for future large-scale implementation. The development of according research competences and international collaborations therefore is the most vital component of this project.
Campo scientifico
- natural scienceschemical sciencesinorganic chemistryinorganic compounds
- natural scienceschemical sciencesorganic chemistryvolatile organic compounds
- medical and health sciencesclinical medicineoncology
- engineering and technologynanotechnologynano-materials
- natural scienceschemical sciencesanalytical chemistrymass spectrometry
Programma(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SC1-2018-Single-Stage-RTD
Meccanismo di finanziamento
RIA - Research and Innovation actionCoordinatore
32000 Haifa
Israele